Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OIG Report Finds “Inadequacies” In FDA Review Of Employee Activities

This article was originally published in The Tan Sheet

Executive Summary

The "quality and extent" of information provided to FDA by employees seeking to participate in outside activities should be improved by requiring additional details on the nature of the activity, Inspector General Daniel Levinson recommends in a recent report

You may also be interested in...



FDA “outside activity”

The agency "is taking several additional steps to protect against potential conflicts of interest" among employees that will go in to effect as soon as possible, FDA announces June 4. The measures include conducting an annual review of outside activities, expanding the number of FDA employees required to file declarations of their financial holdings and release of an agency-wide "Staff Manual Guide" on outside activities. FDA also announced the results of a review on all outside activities performed by agency employees, which Acting Commissioner Lester Crawford said did not identify any other activities of concern. The review covered more than 1,800 HHS form 520s entitled "request for approval of outside activity" for both paid and unpaid work by FDA employees. FDA announced revisions to its procedure for reviewing outside activities of agency employees on May 18, the same day a House Oversight & Investigations Subcommittee hearing addressed the ethics of outside consulting arrangements by NIH employees...

Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products

FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation

Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products

FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel